Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00501748 · ClinicalTrials.gov registry record · Phase 1
Safety and Tolerability of Rituximab in Neuromyelitis Optica
A Phase 1 study of Neuromyelitis Optica, sponsored by University of California, San Francisco.
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
- 2
- Study locations
NCT00501748: Completed Phase 1 study of Neuromyelitis Optica, sponsored by University of California, San Francisco.
NCT00501748 is a Phase 1 study of Neuromyelitis Optica that has completed, run by University of California, San Francisco. The registered enrollment target is 20 participants, below the 511-participant average among 7 other Neuromyelitis Optica trials with a reported enrollment target (96% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00501748, a Phase 1 study of Neuromyelitis Optica, has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
- 2
- Study locations
Study Summary
The goal of this research study is to investigate whether Rituximab is safe to use in patients suffering from NMO, or who are at high risk for developing NMO. It is thought that NMO is caused by the immune system reacting against the optic nerves and spinal cord. B cells are a part of the immune system that may contribute to the illness. Rituximab is an antibody that depletes B cells. Depletion of these B cells with Rituximab may induce remission of the disease. Because pathological and serological studies suggest that NMO appears to be, at least in part, a B-cell mediated disease Rituximab, is an attractive treatment candidate for this disease.
Conditions Studied
Interventions
- DRUG Rituximab
Study Locations (2)
California
- UCSF MS Center , 350 Parnassus Ave , suite #908 - San Francisco
New York
- The Neurological Institute of New York MS Center - Columbia University Medical Center 710 West 168th Street,
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2004-01 |
| Est. Completion | 2010-12 |
| Phase | Phase 1 |
What the finished NCT00501748 record still lists
NCT00501748 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 511-participant average among 7 other Neuromyelitis Optica trials with a reported enrollment target (96% lower).
The record links to 1 condition, with Neuromyelitis Optica appearing as the primary indexed condition, and to 1 intervention - of which Rituximab is the first listed.
NCT00501748 reports a single indexed study location in California, New York.
Frequently Asked Questions
What is clinical trial NCT00501748 about?
NCT00501748 is a clinical study titled "Safety and Tolerability of Rituximab in Neuromyelitis Optica". The goal of this research study is to investigate whether Rituximab is safe to use in patients suffering from NMO, or who are at high risk for developing NMO. It is thought that NMO is caused by the immune system reacting against the optic nerves and spinal cord. B cells are a part of the immune sys...
What is the current status of trial NCT00501748?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2004-01. Estimated completion is 2010-12.
What conditions does trial NCT00501748 study?
This clinical trial studies the following conditions: Neuromyelitis Optica.
What interventions are being tested in trial NCT00501748?
The interventions under investigation include: Rituximab (DRUG).
Who is sponsoring clinical trial NCT00501748?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00501748 being conducted?
This trial has 2 study locations across California, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neuromyelitis Optica
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
An Open Label Study of the Effects of Eculizumab in Neuromyelitis Optica
COMPLETED · Phase 1
-
Study of the Clinical and Radiological Impact of Ravulizumab in People With Neuromyelitis Optica Spectrum Disorder
RECRUITING
-
Performance and Safety of a Digital Tool for Unsupervised Self-assessment of NMOSD
RECRUITING · NA
-
The Longitudinal CONQUER Study of Rare Neuroimmunologic Disorders
ACTIVE NOT RECRUITING
-
Biobank For MS And Other Demyelinating Diseases
ACTIVE NOT RECRUITING
-
A Pilot Study of Mitoxantrone for the Treatment of Recurrent Neuromyelitis Optica (Devic's Disease)
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia